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The apolipoprotein E (apoE) genotype is an important genetic risk
factor for Alzheimer’s disease (AD). In the central nervous system
(CNS), most apoE is produced by astrocytes and is present in unique
high-density lipoprotein (HDL)-like particles that have distinct proper-
ties from apoE derived from other sources. To develop an efficient
system to produce astrocyte-derived apoE in large quantities, we
produced and characterized immortalized cell lines from primary
astrocyte cultures derived from human APOE knock-in mice. APOE2,
APOE3, and APOE4 expressing cell lines were established that secrete
apoE in HDL-like particles at similar levels, cholesterol composition,
and size as those produced by primary astrocytes. In physiological
buffers, astrocyte-secreted apoE3 and E4 associated equally well with
amyloid-B. Under the same conditions, only a small fraction of AB
formed sodium dodecyl sulfate (SDS)-stable complexes with apoE (E3 N
E4). These immortalized astrocytes will be useful for studying
mechanisms underlying the isoform-specific effects of apoE in the CNS.
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Immortalized astrocyte-derived human ApoE.
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Epidemiological studies have shown that the q4 allele of the
apolipoprotein E gene (APOE) is a strong risk factor for both
Alzheimer’s disease (AD) and cerebral amyloid angiopathy
(CAA), whereas the q2 allele is associated with decreased AD
risk (Greenberg et al., 1995; Strittmatter and Roses, 1996;
Wisniewski et al., 1997). In addition, the q4 allele is associated
with increased morbidity following cerebral hemorrhage (Alberts
et al., 1995) and head trauma (Chapman et al., 2001b) as well as
more rapid progression of disease in patients with multiple
sclerosis (Chapman et al., 2001a). A large body of evidence
suggests that at least part of the effect of APOE isoforms on AD
and CAA risk is mediated by interactions of apoE with the
amyloid-h (Ah) peptide, the primary constituent of amyloid
plaques that accumulate in the brain of AD patients (reviewed in
Holtzman, 2001). ApoE, in an isoform-specific fashion, regulates
the time of onset and amount of Ah deposition via effects on Ah
clearance and fibrillogenesis in APP transgenic mice (Bales et al.,
1997; DeMattos et al., 2004; Fagan et al., 2002; Holtzman et al.,
2000). In addition, it has been proposed that apoE may also
influence AD and other central nervous system (CNS) disorders by
influencing additional biological processes such as neural repair
and inflammation (Buttini et al., 1999; Lynch et al., 2003; Teter,
2000). Understanding the nature of interactions between apoE and
other molecules in the brain is likely to provide important insights
into its normal function as well as its role in disease.
ApoE is a 34-kDa glycoprotein that is highly expressed in the
liver and in the brain (Elshourbagy et al., 1985; Newman et al.,
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lipoproteins such as large very low-density lipoproteins (VLDL) as
well as high-density lipoproteins (HDL). In the cerebrospinal fluid
(CSF), apoE is only present in lipoproteins that are HDL-like in
size (Borghini et al., 1995; LaDu et al., 1998; Pitas et al., 1987b;
Roheim et al., 1979). Interestingly, apoE-containing lipoproteins in
the CSF are produced predominantly, if not exclusively, by cells
within the CNS (Linton et al., 1991). Unlike apoE in plasma
lipoproteins that is present in the same particle along with several
other apoproteins, apoE in the CNS is initially secreted predomi-
nantly by astrocytes in unique HDL-like particles that contain apoE
as the sole apoprotein constituent (Fagan et al., 1999; LaDu et al.,
1998). Glia (astrocytes and microglia) are cells in the CNS that
produce the majority of apoE (Boyles et al., 1985; LaDu et al.,
1998; Nakai et al., 1996; Pitas et al., 1987a; Stone et al., 1997),
with astrocytes appearing to produce the preponderance of this
protein. It has been demonstrated that astrocytes secrete apoE in
nascent HDL-like lipoprotein particles, which contain cholesterol
and phospholipid but lack a cholesteryl-ester core (DeMattos et al.,
2001b; Fagan et al., 1999; LaDu et al., 1998). Since the
physiological activity of apolipoproteins and their interactions
with other molecules (e.g., Ah and receptors) can be markedly
influenced by the size, composition, and type of lipoprotein
particle with which they are associated, it is important to study the
properties and interactions of apoE derived from the CNS or CNS
cells. To this end, we recently reported on a method to purify apoE-
containing lipoproteins from primary astrocyte cultures to facilitate
the characterization of astrocyte-derived human apoE-containing
HDL and their interactions with other molecules present in the
brain (DeMattos et al., 2001b). Although this method has proved
valuable, obtaining large quantities of apoE from primary astrocyte
cultures was challenging. To facilitate the preparation and
purification of large quantities of human apoE-containing lipo-
proteins derived from astrocytes, we have established new lines of
immortalized astrocytes from human APOE-expressing knock-in
mice. Herein, we characterize these cells, the apoE-containing
lipoproteins they secrete, and the interactions of these lipoproteins
with Ah.Materials and methods
Animals
APOE knock-in mice expressing human apoE2, apoE3, or
apoE4 (homozygous) under the control of the endogenous mouse
apoE promoter were generated by a gene replacement strategy
(Knouff et al., 1999; Sullivan et al., 1997, 1998). These mice were
used to produce immortalized astrocytes. Wild-type C57Bl/6 mice
and apoE/ mice (Jackson labs, Bar Harbor, MN) on a C57Bl/6
background were used as controls. Transgenic mice expressing
apoE3 or apoE4 under the control of the glial fibrillary acidic
protein (GFAP) promoter (Fagan et al., 1999; Sun et al., 1998) as
well as APOE knock-in mice were utilized for production of
primary astrocyte culture-derived apoE.
Primary astrocyte cultures
Primary cultures of forebrain astrocytes (N95% pure) were
prepared from individual neonatal (1–2 days old) mice in T75
flasks as described (Rose et al., 1993). Growth medium consistedof Dulbecco’s modified Eagle’s medium/Ham’s F-12 containing
10% fetal bovine serum, 10% horse serum, 1 mM sodium
pyruvate, 100 units/ml penicillin, 100 Ag/ml streptomycin,
250 ng/ml fungizone, and 10 ng/ml epidermal growth factor.
Immortalization of APOE knock-in mice astrocytes
After culturing primary astrocytes in T75 flasks for 7 days, the
cultured cells were dislodged by 0.05% trypsin and 0.02%
ethylenediaminetetraacetic acid (EDTA), triturated, and then
subcultured on 100-mm petri dishes at a density of 2–3  105
cells/dish. After an overnight incubation, the cells were transfected
with 10 Ag of the plasmid pSV3-neo containing the SV40 T
antigen early regions and the neomycin resistance gene (Morikawa
et al., 2001; Southern and Berg, 1982) using FuGENE 6 (Roche
Applied Science, Indianapolis, IN) according to the manufacturer’s
protocol. Three days after transfection, Geneticin (Invitrogen
Corporation, Grand Island, NY) was added to select neomycin-
resistant colonies. The concentration of Geneticin was gradually
increased from 200 to 800 Ag/ml. After 3 weeks, single colonies of
cells were isolated with cloning discs dipped in 0.05% trypsin/
0.02% EDTA and placed in a 24-well plate.
Clones were expanded in a 12-well and then a 6-well plate and
were then maintained in growth medium with 200 Ag/ml Geneticin
(regular media). The immortalized hypothalamic neuronal cell line
GT1–7 (Mellon et al., 1990) was used as a neuronal cell line
control for characterization and comparison of cell lines and
maintained in Dulbecco’s modified Eagle’s medium containing
10% fetal bovine serum. Wild-type mouse embryonic fibroblasts
(MEF-1 cells), fibroblasts homozygous for disruption of the low
density lipoprotein receptor (LDLR)-related protein (LRP) gene
(MEF-2 cells), and fibroblasts homozygous for disruption of both
the LRP and the LDL receptor genes (MEF-4 cells) were kindly
provided by Dr. Guojun Bu (Washington University in St. Louis,
School of Medicine) (Narita et al., 2002).
Media and cell harvesting
Cell clones were plated in 6-well plates and, after reaching
confluency, were rinsed two times with phosphate-buffered saline
(PBS, pH 7.4) followed by the addition of 800 Al of serum-free
media, Dulbecco’s modified Eagle’s medium/Ham’s F-12 con-
taining 1% N-2 supplement (Invitrogen Corporation), 100 units/ml
penicillin, 100 Ag/ml streptomycin, and 250 ng/ml fungizone.
Twenty-four hours later, conditioned media were harvested and
protease inhibitors (Complete protease inhibitor cocktail tablets;
Roche Applied Science and 1 mM phenylmethylsufonyl fluoride
(PMSF)) were added to the media. Cells were washed with PBS
and resuspended in 1 ml of cell lysis buffer containing 0.5%
Nonidet P-40 and protease inhibitors (Complete protease inhibitor
cocktail tablets and 1 mM PMSF). Human CSF, obtained as
described (Fagan et al., 2000), and mouse brain lysates were used
as controls for the media and cell lysates, respectively.
ApoE ELISA
Sandwich ELISA for human apoE was performed as described
(Mobley et al., 1989), except that the coating antibody was a
mouse monoclonal antibody (WU E-4) raised against human apoE
(Krul et al., 1988), and the detection antibody was a goat
polyclonal antibody (Calbiochem, San Diego, CA) raised against
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equally. Recombinant human apoE (Invitrogen Corporation) was
used for standards.
Western blot analysis
Protein concentrations were determined using a bicinchonic
acid (BCA) protein assay kit (Pierce Biotechnology Incorporation,
Rockford, IL). Sodium dodecyl sulfate (SDS)-polyacrylamide gel
electrophoresis (PAGE) was performed using 7.5–12.5% gels for
separating and 5% for stacking with established methods
(Laemmli, 1970). Following SDS-PAGE, proteins were transferred
to a nitrocellulose membrane. GFAP proteins were detected by
incubation with anti-GFAP antibodies (Santa Cruz Biotechnology,
Santa Cruz, CA; 1:100 dilution) and the neuronal specific protein
NeuN was detected with anti-NeuN antibodies (Chemicon Interna-
tional Incorporation, Temecula, CA; 1:100 dilution). SV40 T
antigen was detected with an anti-SV40 T antigen antibody (gift
from R. Weiner, University of California, San Francisco; 1:1000
dilution) and human apoE proteins were detected with the
antihuman apoE monoclonal antibody (WU E-4; 1:1000 dilution).
Mouse LRP and LDLR were detected with the rabbit anti-LRP and
LDLR antibody (gift from G. Bu., Washington University in St.
Louis, MO; both 1:2000 dilution). Immunoreactivity was visual-
ized with enhanced chemiluminescence (Pierce Biotechnology
Incorporation). Images were captured using the Kodak Image-
Station 440CF. Densitometry and standard curves were generated
using the Kodak 1D Image Analysis software.
Nondenaturing gradient gel electrophoresis (NDGGE)
Samples were electrophoresed on a nondenaturing 4–25%
polyacrylamide gradient gel as described (Holtzman et al., 1999),
transferred to nitrocellulose membrane, and probed with a
polyclonal antibody to human apoE (Biodesign International,
Saco, ME; 1:1000 dilution). Immunoreactivity was visualized with
enhanced chemiluminescence (Pierce Biotechnology Incorpora-
tion). The size of the apoE-containing lipoproteins was estimated
by comparing their location following NDGGE to size markers
(Amersham Bioscience, Piscataway, NJ) with known hydrated
diameters.
Fractionation
Serum-free conditioned medium (SFCM) from immortalized
astrocyte cell lines expressing apoE2, apoE3, or apoE4 was
concentrated 100-fold with a 10-kDa cut-off filter (Millipore
Corporation, Bedford, MA) prior to fractionation. One milliliter of
concentrated SFCM was fractionated by gel filtration chromato-
graphy (Biologic System, Bio-Rad Laboratories, Hercules, CA)
with tandem Superose-6 HR 10/30 columns (Amersham Bio-
science) in 150 mM NaCl with 1 mM EDTA, and 0.02% sodium
azide as described (Fagan et al., 2000). Fractions of 400 Al each
were collected and analyzed.
Total cholesterol and phospholipid analysis
Total cholesterol in fractions was quantified with the Red
Cholesterol Assay Kit (Molecular Probes, Eugene, OR) and
phospholipid was quantified with the phospholipids B kit (Wako,
Richmond, VA).Purification of apoE particles and electron microscopy
To purify astrocyte-secreted apoE-containing lipoproteins,
immunoaffinity columns were prepared as described (DeMattos
et al., 1998) using a mouse monoclonal antibody to human apoE
(WU E-4). ApoE was then purified from the conditioned media
with the anti-apoE columns as described (DeMattos et al., 1998,
2001b). Purified apoE-containing lipoproteins were visualized by
electron microscopy as described (Wang et al., 2002). Purified
apoE-containing lipoproteins from immortalized astrocytes were
adsorbed to glow-discharged carbon-coated copper grids. Grids
were washed with two drops of deionized water and stained with
two drops of freshly prepared 0.75% uranyl formate. Specimens
were inspected with a Philips Tecnai 12 electron microscope
operated at 120 kV and images were taken at a nominal
magnification of 52,000 using low-dose procedures.
ApoE particle/Ab complex formation and assay
Synthetic human Ah 1–40 peptide (Ah40) (American Peptide
Company Incorporation, Vista, CA) was dissolved at 2 mM in
100% dimethyl sulfoxide (DMSO) or in formic acid. For experi-
ments in which Ah was dissolved in formic acid, vials of
lyophilized Ah40 (1 mg) were solubilized in 98% formic acid to
a final concentration of 10 mg/ml (2 mM). Immediately prior to
any mixing experiments with apoE-containing lipoproteins, the pH
of the Ah stock was neutralized by performing a 1:1000 dilution
into PBS containing 10 mM Tris pH 7.4. For experiments with
DMSO, 1 Al of a 2 mM Ah stock solution was diluted into 15 Al of
PBS (pH 7.4). Two microliters of this 0.125 mM Ah solution was
gently mixed with 18 Al of purified apoE-containing lipoproteins
and incubated for 2 h at room temperature with Ah40 in PBS (pH
7.4) in a total volume of 20 Al. After 2 h, 5 nonreducing Laemmli
buffer was added to the mixture and complexes were separated on
10–20% polyacrylamide SDS/Tricine gels (Invitrogen Corpora-
tion). Alternatively, the gel running buffer (Tris-Glycine Native
Running Buffer, Invitrogen Corporation) in the absence of
detergent was combined with apoE/Ah mixtures and run on
nondenaturing 3–30% polyacrylamide gradient gels in the absence
of 2-mercaptoethanol, transferred to nitrocellulose membranes, and
probed with anti-Ah monoclonal antibodies 2G3 (gift from Eli
Lilly; 1:2000 dilution), 3D6 (gift from Eli Lilly; 1:1000 dilution),
and 4G8 (Signet Laboratories Incorporation, Dedham, MA; 1:1000
dilution), or with a mouse monoclonal antibody to human apoE
(WU E-4; 1:1000 dilution). The amount of Ah complexed with
apoE-containing lipoproteins was estimated with densitometry
using the Kodak ImageStation 440CF.Results
Isolation and characterization of immortalized cells
We transfected primary astrocyte cultures derived from post-
natal day P1 or P2 APOE2, APOE3, and APOE4 knock-in mice
with a plasmid containing the SV40 T antigen and the selectable
marker neo. Several weeks after transfection, we were able to
obtain multiple cell clones derived from APOE2 (n = 34), APOE3
(n = 22), and APOE4 (n = 22) mice (Table 1). We determined the
concentration of human apoE in serum-free conditioned media
(SFCM) from each cell line. After 24 h of incubation, apoE levels,
Table 1
Quantitation of the level of apoE present in serum-free conditional media from immortalized astrocytes derived from APOE2, APOE3, and APOE4 knock-in
mice
Cells were grown in 6-well plates. After reaching confluency, 1 ml of serum-free media was placed on the cells and following 24 h the media were analyzed for
apoE concentration by ELISA. ApoE values are expressed as ng per mg of protein in cell lysates. The highlighted cell lines are the highest expressing lines that
were further characterized.
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secreting clones. These apoE levels overlap with levels found in
the media derived from primary cultured astrocytes (0.5–2 Ag/ml)
prepared in the same fashion (Sun et al., 1998). We then
determined the amount of apoE in SFCM from each clone
normalized to the amount of cellular protein (Table 1). Cell lines
with the highest apoE expression levels (apoE2–5, apoE3–12, and
apoE4–7) were characterized in more detail. Cells from all three
cell lines exhibited flat, polygonal shapes and formed monolayers
that were similar in appearance to primary astrocyte cultures
(Fig. 1). Cell lysates and SFCM from these immortalized astrocytes
were analyzed by SDS-PAGE followed by Western blotting for a
variety of proteins. In SFCM, apoE was detected as a 34- to 36-
kDa doublet from APOE2-, APOE3-, and APOE4-expressing cells
that comigrated with apoE present in human CSF (Fig. 2A). In
nonreducing gels, an ~80-kDa apoE dimer was detected in cells
expressing apoE2 and apoE3 due to the presence of one or two
cysteine residues, respectively, in each molecule (data not shown).
The astrocyte-specific 50-kDa protein GFAP was detected in cell
lysates derived from primary astrocytes from wild-type mice as
well as from all clones of immortalized astrocytes that wereanalyzed (Fig. 2B). GFAP was not detected in cell lysates derived
from the neuronal cell line GT1–7 (Fig. 2B). Neu-N, a 46- to 66-
kDa neuronal-specific protein, was detected in mouse brain
homogenates but not in cell lysates from immortalized astrocytes
(Fig. 2C). Two of the main receptors for apoE, the low-density
lipoprotein receptor (LDLR) as well as the LDLR-related protein
(LRP), were expressed by each APOE2, APOE3, and APOE4
expressing cell lines that were assessed (Fig. 2D). The SV40 T
antigen was also detected in Western blots of cell lysates from
immortalized astrocyte clones (data not shown), demonstrating that
the cell lines were derived from cells stably transfected with the
SV40 T antigen-containing plasmid.
Purification and size analysis of apoE-containing lipoproteins
secreted by immortalized astrocytes
Primary astrocytes secrete nascent murine and human apoE
into apoE-containing HDLs that are disc-like in appearance since
they contain cholesterol and phospholipid but no cholesteryl-ester
core (DeMattos et al., 2001b; Fagan et al., 1999; LaDu et al.,
1998). To determine if the apoE2-, apoE3-, and apoE4-secreting
Fig. 1. The morphology of apoE-secreting immortalized astrocytes is similar to that of primary astrocytes. Phase contrast images of confluent (A–C) and
subconfluent cultures (F–G) of immortalized astrocytes that secrete (A) apoE2, (B and F) apoE3, and (C and G) apoE4 revealed that the cell lines form
monolayers with a bcobblestoneQ appearance that is of similar morphology to that seen from primary cultured murine astrocytes derived from P1 mice (D and E).
Scale bar in E equals 90 Am.
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concentrated SFCM as well as immunoaffinity purified apoE
particles from these cells and assessed them using nondenaturing
gradient gel electrophoresis (NDGGE) followed by Western
blotting as well as electron microscopy. Analysis of ApoE
present in SFCM and after immunoaffinity purification by these
methods reveals particles ranging in diameter from ~7 to 17 nm
(Figs. 3A and B). In some experiments, there were no always
discreet bands of particles in the larger size range (12–17 nm) as
assessed by NDGGE; however, there was no consistent difference
between the apoE isoforms or cell lines in this regard. The size of
these particles is very similar to that seen with particles derived
from primary astrocytes, 8–17 nm (Fagan et al., 1999; DeMattos
et al., 2001a,b and see Fig. 7). The apparent larger diameter of
apoE in human CSF is consistent with the fact that apoE in CSF
acquires a cholesteryl-ester core (Fig. 3A). No apoE immuno-
reactivity was detected in SFCM derived from apoE/ astrocytes
(Fig. 3A). Analysis of apoE particles purified by immunoaffinity
chromatography by SDS-PAGE followed by Western blot
revealed that apoE was still present as a 34- to 36-kDa doublet
(Fig. 3C) as was seen with SFCM from these cells. In addition,
we analyzed the appearance of purified apoE particles from these
cells by electron microscopy (Fig. 4). Electron microscopyimages of immunoaffinity purified ApoE particles from these
cells revealed predominantly disc-like particles ranging in
diameter from 8 to 19 nm. The size and morphology distribution
of ApoE2-, E3-, and E4-containing particles here are virtually
identical to those observed for ApoE particles secreted by
primary astrocytes (DeMattos et al., 2001b).
Immortalized astrocytes secrete apoE in HDL-like lipoproteins
Primary astrocytes secrete apoE in nascent HDL containing
similar amounts of apoE, cholesterol, and phospholipid (DeMattos
et al., 2001b; Fagan et al., 1999; LaDu et al., 1998). To determine if
apoE particles secreted by immortalized astrocytes were similar in
composition to particles secreted by primary astrocytes, we
collected SFCM from an immortalized astrocyte cell line secreting
apoE3, concentrated it, and subjected it to size exclusion
chromatography. ApoE and cholesterol were at highest concen-
trations in fractions 30–48, which corresponds in size to HDL-like
lipoproteins seen in plasma, CSF, and from primary astrocyte
cultures (Fig. 5) (Fagan et al., 1999, 2000). Superimposition of the
same data from primary astrocytes revealed similar levels of apoE
and cholesterol in overlapping fractions (Fig. 5; Fagan et al., 1999;
Sun et al., 1998). The mass of apoE to cholesterol was in the range
Fig. 2. Immortalized astrocytes from APOE knock-in mice express glial and not neuronal markers. (A) ApoE (40 ng) from serum-free conditioned media or
(B and C) cell lysates (40 Al, 10–20 Ag protein/lane) were subjected to 12% SDS-PAGE followed by Western blot. (A) ApoE is present in media from E2, E3,
and E4 secreting cells but not in media from apoE/ astrocytes. H-CSF = human CSF containing 40 ng apoE was loaded as a positive control. (B) Western
blot for the astrocyte-specific protein GFAP reveals that several lines of immortalized astrocytes express GFAP. No GFAP is detected in cell lysates (10 Ag
protein/lane) from the hypothalamic neuronal cell line GT1–7. (C) Western blot for the neuronal-specific protein Neu-N reveals the presence of Neu-N in
mouse brain lysates but not in the immortalized astrocyte cell lines. (D) Cell lysates (10 Ag protein/lane) from mouse embryonic fibroblasts (MEF)-1
(expressing LRP and LDLR), MEF-2 (lacking LRP expression), MEF-4 (lacking LRP and LDLR expression), and apoE2, E3, and E4 expressing astrocyte
cell lines, were subjected to 3–8% SDS-PAGE followed by Western blot for LRP and LDLR. Three representative cell lines express the apoE receptors LRP
and LDLR.
M. Morikawa et al. / Neurobiology of Disease 19 (2005) 66–76 71of 3–5:1 which is just slightly higher than that found in particles
derived from primary astrocytes (2–3:1) (DeMattos et al., 2001b).
Analysis of apoE and cholesterol in apoE2 and apoE4 particles
revealed similar particle composition.Fig. 3. Human apoE secreted by immortalized astrocytes is present in HDL-like par
to 1 ml. Following apoE ELISA, the amount of conditioned media containing the i
by nondenaturing gradient gel electrophoresis (NDGGE 4–25%) followed by Wes
(600 ng) derived from immortalized astrocytes was first immunoaffinity purified on
7- to 17-nm particles. In (A), hCSF = human CSF, apoE/ is conditioned media f
diameter, in nanometers, of known proteins run as standards. (C) SDS-PAGE of im
followed by Western blot for apoE. Fifty nanograms of apoE was loaded per lanInteraction of astrocyte-secreted apoE with Ab
Prior experiments have shown that cell line-derived apoE can
form an SDS-stable complex with Ah (apoE3 N apoE4) (LaDu etticles. (A) Five milliliters of serum-free conditioned media was concentrated
ndicated amount of apoE was loaded into each lane. Samples were analyzed
tern blot for apoE. The same analysis was done in (B) except that the apoE
an anti-apoE column. ApoE secreted by the astrocyte cell lines is present in
rom apoE/ astrocytes. Size markers in (A) and (B) represent the hydrated
munoaffinity purified apoE-containing HDL from immortalized astrocytes
e. ApoE is seen as a doublet at ~34–35 kDa.
Fig. 4. Electron microscopic image of negatively stained immunoaffinity
purified apoE3-containing lipoproteins from immortalized astrocytes. Scale
bar is equal to 50 nm.
Fig. 5. Size exclusion chromatography of serum-free conditioned media
from a human apoE3-secreting immortalized astrocyte cell line (squares)
and primary astrocyte cultures from an apoE4-transgenic mouse (Fagan
et al., 1999) (triangles) reveal that apoE and cholesterol are colocalized.
One hundred milliliters of serum-free conditioned media derived from
apoE3-line 12 and 50 ml from primary cultures from apoE4-transgenic mice
were was concentrated to 1 ml and then fractioned via size exclusion
chromatography. Four hundred-microliter fractions were analyzed for (A)
apoE protein by ELISA and (B) cholesterol. ApoE and cholesterol are
colocalized in the plasma HDL size range indicating that apoE is present in
HDL-like particles.
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derived apoE, we incubated immunoaffinity purified apoE3 and
apoE4 (2 Ag) with Ah40 (1 Ag) for 2 h (molar ratio apoE/Ah 1:4.5)
and looked for evidence of complex formation by denaturing as
well as nondenaturing gel electrophoresis. Under denaturing
conditions, N99% of the Ah was present as monomers, dimers,
and trimers as visualized after a 30-s exposure of the Western blot
(Fig. 6A). When Ah is first dissolved in formic acid instead of
DMSO and then diluted, almost all the Ah is monomeric with
almost no Ah dimers and trimers seen (data not shown). After a
longer exposure time (5 min), an apparent apoE3-Ah complex
running at ~40 kDa could be detected, likely representing an SDS-
stable apoE–Ah complex (Fig. 6B) that has previously been
described (Aleshkov et al., 1997; LaDu et al., 1994, 1995; Yang et
al., 1997). A faint band likely representing an apoE4/Ah complex
could be seen at even longer exposure times (data not shown). We
have seen very similar results utilizing apoE3 and apoE4 derived
from primary astrocytes (data not shown). After striping the same
membrane followed by apoE Western blot, a 34-kDa apoE was
detected (Fig. 6C). To mimic more physiological interactions that
might occur between apoE (secreted by glia) and soluble Ah
(predominantly secreted by neurons) in the brain interstitial fluid
(ISF) space, we also incubated immunoaffinity isolated apoE
particles (2 Ag) with Ah (1–5 Ag) (molar ratio apoE/Ah range
1:4.5–1:22.5) and looked for the presence of complex formation
under nondenaturing conditions. To investigate the possibility that
apoE interaction with Ah results in the formation of complexes that
could be SDS sensitive, the apoE and Ah mixtures were loaded
and analyzed by NDGGE (in the absence of detergent) followed by
Western blotting. Interestingly, a much larger percentage of Ah
interacted with apoE-containing HDL-like particles under these
nondenaturing (5–20%) as compared to denaturing conditions
(b1%) (Figs. 7C and B) as determined by densitometry. Ah
comigrated with the larger apoE-containing HDLs that were ~10–
17 nm in size, suggesting greater interaction with larger particles
containing more lipid (Fig. 7B). There was no clear differencebetween the amount of Ah that associated with apoE3- or E4-
containing HDL under these conditions. In experiments with
apoE2 and Ah, we found qualitatively similar results as with
apoE3 and E4 (data not shown). In addition to comparing the
interaction between Ah and astrocyte cell line-secreted apoE, we
also examined the interaction between Ah and apoE particles
Fig. 6. Interaction of immortalized astrocyte-derived apoE isoforms with Ah40 under denaturing conditions by SDS-PAGE. Immunoaffinity purified apoE3 and
apoE4 (2 Ag, respectively) was incubated with synthetic human Ah40 (1 Ag). Following their incubation for 2 h at room temperature, apoE-Ah complex
formation was assessed under denaturing conditions by 10–20% SDS-Tricine-PAGE. Gels were then analyzed by Western blot for Ah (A and B) and apoE (C).
Short exposure (30 s) of the blot shown in (A) and long exposure of the blot (5 min) is shown in (B). Ah monomers, dimers, and trimers were detected after
short exposure (A). After long exposure, an apoE3/Ah complex was detected at ~40 kDa. The Ah in this complex is b1% of the Ah loaded in the lane as
detected by densitometry. After stripping the same membrane followed by Western blot for apoE, apoE was detected with a molecular weight of ~34 kDa (C).
Size markers are in kilodaltons (kDa).
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ratios of apoE/Ah of 1:1 or 1:0.5 were utilized (600 ng apoE, 70 or
37.5 ng Ah). As with our cell line-secreted apoE, apoE3 and apoE4
were in particles that ranged in size from ~8 to 17 nm (Fig. 7C).
After mixing Ah40 with apoE3 and apoE4, ~20% of the Ah
comigrated with the larger 10- to 17-nm particles (Fig. 7D), as was
seen with the astrocyte cell line-derived particles (Fig. 7B).
Qualitatively, there was no clear isoform-specific difference in
the interaction.Discussion
ApoE plays an important role in plasma lipoprotein metabo-
lism. In the CNS, its function is less clear; however, APOE allelic
differences are associated with differential risk for developing AD,
CAA, as well as for altered clinical progression following the onset
of certain CNS diseases such as multiple sclerosis, brain
hemorrhage, and trauma (for a review, see Holtzman, 2001; Teter,
2000). In order to better understand the normal biological role of
apoE and its role in the pathogenesis of AD and other CNS
diseases, it would be useful to study apoE using preparations of
apoE-containing lipoproteins that are similar to that found in the
parenchyma of the CNS. While we have previously developed a
method to purify apoE-containing HDL particles from primary
astrocytes, obtaining large quantities of apoE from primary cultures
for detailed biochemical studies remains a challenging task due to
the large number of animals required and the relatively small
amount of apoE that can be purified from each set of cultures. To
facilitate studies of astrocyte-derived human apoE, we have
established new lines of immortalized astrocytes from human
APOE-expressing knock-in mice. We confirmed that these cell
lines express astrocytic but not neuronal proteins. In addition, wefound that several cell lines secrete apoE2, E3, and E4 in HDL-like
lipoproteins that have similar biochemical and structural properties
to primary astrocyte-derived apoE particles, including lipid
content, morphology, and molecular size. We also examined the
interaction of apoE-containing lipoproteins derived from these
cells with Ah40. While we found differential interactions between
apoE3 and apoE4 with Ah40 in regard to sodium dodecyl sulfate
(SDS)-stable complex formation (Fig. 6B), a very small percentage
of Ah (b1%) formed an SDS-stable complex. In contrast, a
relatively large percentage of Ah40 formed a complex between
apoE3 and apoE4 particles in the presence of physiological buffers
and there was a similar degree of association between the isoforms
(Figs. 7B and D). This suggests that under physiological conditions
such complexes may be important to modulate the ability of apoE
to influence soluble Ah clearance and diffusion in the CNS
parenchyma. These cell lines should be useful tools for studying
cell biological, biochemical, and other properties of astrocyte-
derived apoE-containing lipoproteins and their role in health and
disease.
The apoE particles secreted by the cell lines appear to have
properties very similar to lipoprotein particles secreted by primary
astrocytes. We and others have previously shown that primary
astrocytes secrete apoE as nascent HDL-like lipoproteins that (1)
range in size from 7 to 17 nm; (2) are disc-like in appearance; (3)
contain apoE, phospholipids, and cholesterol but no cholesteryl
ester core; and (4) contain apoE as their sole apoprotein constituent
(DeMattos et al., 2001b; Fagan et al., 1999; LaDu et al., 1998;
Pitas et al., 1987a). Virtually identical properties were seen from
the astrocyte cell line secreted apoE. Importantly, compared to
apoE particles that are secreted by transfected cell lines, the nascent
astrocyte-secreted particles contain a much greater amount of
cholesterol. For example, the mass ratio of apoE/cholesterol in
apoE particles secreted by a neuronal cell line was 73–88:1
Fig. 7. Interaction of immortalized astrocyte-derived and primary astrocyte-
derived apoE isoforms with Ah40 under nondenaturing conditions as
assessed by NDGGE. (A and B) Immunoaffinity purified apoE3 and apoE4
from immortalized astrocytes were incubated with synthetic Ah40.
Following their incubation for 2 h at room temperature, apoE–Ah complex
formation was assessed under nondenaturing conditions by NDGGE. Gels
were then analyzed by Western blot for apoE (A) and Ah (B). ApoE is
present in HDL-like particles ranging in size from 7 to 17 nm. The amount
of Ah that associates with the purified apoE3- and apoE4-containing HDL
when analyzed under nondenaturing conditions is similar. Ah associates
with the larger 10- to 17-nm HDL-like particles. (C and D) Immunoaffinity-
purified apoE3 and apoE4 (C) from primary astrocyte cultures were mixed
with Ah40 that had previously been dissolved in formic acid. After
resolving the complexes by NDGGE, the relative amount of Ah associated
with apoE particles was determined by 125I-linked to streptavidin followed
by phosphorimager quantitation (D). Purified apoE3 and apoE4 were seen
in particles that ranged in size from ~8 to 17 nm (C). After mixing Ah40
with apoE3 and apoE4 (molar ratio: apoE vs. Ah = 1:0.5 (left column) and
1:1 (right column), respectively), Ah comigrated with the larger 10- to
17-nm particles (D) as was seen in (B). Phosphorimager analysis revealed
that ~20% of the Ah had associated with the apoE particles. Size markers
represent the hydrated diameter, in nanometers, of proteins run as standards.
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with the immortalized astrocytes is ~3–5:1, similar to that seen
with primary astrocytes. The apoprotein/lipid ratio of lipoprotein
particles can markedly influence properties such as receptor
binding (Narita et al., 2002) and interactions with other moleculessuch as Ah (LaDu et al., 1994, 1995; Tokuda et al., 2000).
Importantly, two recent studies demonstrate that if apoE is poorly
lipidated in the CNS due to the absence of the protein ATP-binding
cassette transporter A-1 (ABCA1), apoE particles are rapidly
metabolized in the brain resulting in levels that are 2% of normal in
the CSF and b20% of normal in the cortex (Hirsch-Reinshagen et
al., 2004; Wahrle et al., 2004). Thus, studying apoE derived from
astrocyte cell lines that are lipidated by the cellular machinery
possessed by these cells is likely be very useful to better model
apoE’s effects and interactions in the CNS.
ApoE has been demonstrated to modulate Ah clearance and
fibrillogenesis both in vitro (Beffert et al., 1999; Castano et al.,
1995; Evans et al., 1994; Koistinaho et al., 2004; Ma et al., 1994;
Yang et al., 1997, 1999) and in vivo (Bales et al., 1997; DeMattos
et al., 2004; Holtzman et al., 2000; Shibata et al., 2000). In vivo,
human apoE suppresses the onset of Ah deposition and sub-
sequently results in an isoform-specific effect (E4 N E3 N E2) on
the amount of Ah deposition, fibril formation, and neuritic plaque
formation (Fagan et al., 2002; Holtzman et al., 2000). To date,
while the effects of apoE on Ah clearance have been seen in in
vitro and in vivo studies, an isoform-specific effect of apoE has
been difficult to identify (DeMattos et al., 2004; Koistinaho et al.,
2004). Some in vitro studies do show differential effects of apoE
isoforms on Ah fibrillogenesis (E4 N E3) with some studies
demonstrating that apoE inhibits and others showing apoE
enhances Ah fibril formation (Castano et al., 1995; Evans et al.,
1994; Ma et al., 1994). Importantly, while lipidated apoE has been
used in some Ah binding and association studies (LaDu et al.,
1994, 1995; Tokuda et al., 2000), lipidated apoE has not been
extensively utilized in studies examining the effect of apoE on Ah
clearance and fibrillogenesis. The apoE particles derived from
astrocytes should provide a novel tool to assist in studying the
effects of apoE on Ah fibrillogenesis and clearance using more
physiological reagents. This should allow for a better determi-
nation of the extent to which apoE is influencing Ah conformation,
clearance, or both, and provide new insights into the effects of
apoE on Ah in the interstitial fluid of the brain. Such effects are
likely to be relevant to mechanisms underlying Ah deposition and
toxicity in AD and CAA.
In conclusion, apoE influences risk for AD, CAA, and outcome
after certain CNS diseases. Studies of apoE that is in unique HDL-
like lipoproteins secreted by astrocytes may allow for better
modeling of both normal and disease-related functions of apoE in
the brain. Our studies suggest that Ah40 can directly interact with
astrocyte-derived apoE3- and apoE4-containing lipoproteins to a
similar degree in physiological buffers. The immortalized astrocyte
cell lines that express human apoE isoforms will be a useful tool to
study astrocyte-derived apoE and its functions.Acknowledgments
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